Surprisingly, treatment with L-NAME, an inhibitor of NOS2, did not significantly affect body weight and tumor burden or lifespan despite decreased serum levels of nitric oxide to normal baseline (Figure S4A and S4B, Figure S5A and S5B). This evidence concerns the gene NOS2 and neoplasm.